A Look At Regeneron Pharmaceuticals (REGN) Valuation After Japan’s Approval Of Dupixent For Bullous Pemphigoid

Regeneron Pharmaceuticals (REGN) is back in focus after Japan approved Dupixent as the first targeted treatment for adults with moderate to severe bullous pemphigoid, expanding the drug’s reach in a ...
Yahoo Finance

How Investors Are Reacting To Regeneron (REGN) Securing Japan’s First Targeted Bullous Pemphigoid Therapy Approval

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
pharmaphorum

Dupixent delivers in two skin disease trials

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the drug ...
Hosted on MSN

Regeneron (REGN) and Sanofi announce Dupixent approval in Japan to treat bullous pemphigoid

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 8 Best Debt Free Stocks to Buy Right Now. On March 24, 2026, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi (SNY) announced that ...
Pharmabiz

Sanofi & Regeneron’s Dupixent receives Japanese marketing approval to treat adults with moderate-to-severe bullous pemphigoid

The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of adults with moderate-to-severe bullous ...
Zacks.com on MSN

SNY & REGN's Dupixent Gets EU Approval for Pediatric Use in Urticaria

Sanofi SNY and its partner Regeneron Pharmaceuticals REGN announced that the European Commission (EC) has approved the expanded use of their blockbuster drug, Dupixent, for the treatment of ...

Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma

KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027KT-621 BROADEN2 Phase 2b atopic dermatitis (AD) trial ...

Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)

In addition to BP, Dupixent is approved in Japan in certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), prurigo nodularis, chronic spontaneous ...
Pharmabiz

European Commission approves Sanofi & Regeneron’s Dupixent to treat young children with chronic spontaneous urticaria

European Commission approves Sanofi & Regeneron’s Dupixent to treat young children with chronic spontaneous urticaria: Paris Wednesday, April 15, 2026, 09:00 Hrs [IST] The Europ ...

Kymera Therapeutics, Inc.: Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to ...

KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027 KT-621 BROADEN2 Phase 2b atopic dermatitis (AD) trial ongoing, with data expected by mid-2027 Fast Track de ...
PharmiWeb

Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria

Approval in CSU for children two to 11 years of age is based on data from the LIBERTY-CUPID clinical study program, including an extrapolation of efficacy data showing that Dupixent significantly ...